Business · 20/12/2018
FDA Extends Comment Period for Proposed Rule on Clinical Investigations
The Food and Drug Administration (FDA) is extending the comment period for a proposed rule regarding Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations, following a request for an extension from interested persons.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →